8-K 1 y98160e8vk.txt HALSEY DRUG CO., INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2004 HALSEY DRUG CO., INC. 616 N. North Court, Suite 120, Palatine, Illinois 60067 (847-705-7709) I.R.S. Employer Incorporated under the laws Commission File Number Identification Number of State of New York 1-10113 11-0853640 Item 5. Other Events On June 10, 2004, Halsey Drug Co., Inc. (the "Company") issued a press release disclosing (a) the completion of a $14.0 million offering of the Company's convertible debentures pursuant to the Debenture and Share Purchase Agreement executed by the Company in February 2004, and (b) an amendment to the Debenture and Share Purchase Agreement to (i) increase the principal amount of debentures issuable thereunder from $14.0 million to $17.5 million and (ii) extend the time to complete such additional financing from June 5, 2004 to June 30, 2004. A copy of the Company's press release is attached as Exhibit 99.1 hereto. Item 7. Financial Statements and Exhibits. (b) Exhibits Exhibit Number Description ------ ----------- 99.1 Press Release of Halsey Drug Co.,Inc. dated June 10, 2004. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. HALSEY DRUG CO., INC. By: /s/ Peter A. Clemens --------------------------- Peter A. Clemens Senior Vice President & Chief Financial Officer Date: June 10, 2004 3 EXHIBIT INDEX ------------- Exhibit Number Description ------ ----------- 99.1 Press Release dated June 10, 2004. 4